Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients

Cesare Cuspidi, Stefano Meani, Cristiana Valerio, Veronica Fusi, Carla Sala, Meilikemu Maisaidi, Alberto Zanchetti

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background. The 2003 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines recommend angiotensin II receptor antagonists (AIIRAs) as a first-line therapy in hypertensives with left ventricular hypertrophy (LVH). Aim. We investigated the long-term effects of an AIIRA-based therapy on left ventricular (LV) structure and geometry in previously, unsatisfactorily treated essential hypertensive patients. Methods: Sixty-eight consecutive patients referred to our hypertension hospital outpatient clinic with: (i) LVH (LV mass index, LVMI ≥51 g/m2.7 in men and ≥47 g/m2.7 in women), (ii) uncontrolled clinic blood pressure BP≥140 and/or 90mmHg) and (iii) antihypertensive therapy not including angiotensin-converting enzyme (ACE) inhibitors or AIIRAs were selected for this study. Two-dimensionally guided M-mode echocardiograms were carried out at baseline and after 6, 12, 18 and 24 months of follow-up. In all patients, losartan (50-100 mg/day, mean dose 82 mg/day) was added as first step to the previous therapy. Additional drugs, tailored to the single patient, were added, if necessary, to achieve target BP values (v140/90 mmHg). Results. Overall, 59 patients completed the study with the primary efficacy measurements (LVMI) at all appropriate times. A significant reduction in both clinic systolic BP and diastolic BP was found across the entire period of study respect to baseline (-17/10, -22/12, -24/13 and -26/14 mmHg at 6, 12, 18 and 24 months, p

Original languageEnglish
Pages (from-to)107-115
Number of pages9
JournalBlood Pressure
Volume15
Issue number2
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Angiotensin Receptors
Losartan
Left Ventricular Hypertrophy
Angiotensin Receptor Antagonists
Hospital Outpatient Clinics
Therapeutics
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Guidelines
Blood Pressure
Hypertension
Pharmaceutical Preparations

Keywords

  • Angiotensin II receptor blockade
  • Concentric hypertrophy
  • Hypertension
  • Left ventricular regression

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients. / Cuspidi, Cesare; Meani, Stefano; Valerio, Cristiana; Fusi, Veronica; Sala, Carla; Maisaidi, Meilikemu; Zanchetti, Alberto.

In: Blood Pressure, Vol. 15, No. 2, 04.2006, p. 107-115.

Research output: Contribution to journalArticle

Cuspidi, Cesare ; Meani, Stefano ; Valerio, Cristiana ; Fusi, Veronica ; Sala, Carla ; Maisaidi, Meilikemu ; Zanchetti, Alberto. / Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients. In: Blood Pressure. 2006 ; Vol. 15, No. 2. pp. 107-115.
@article{dceb33461d7846938c2632e41a50ac24,
title = "Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients",
abstract = "Background. The 2003 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines recommend angiotensin II receptor antagonists (AIIRAs) as a first-line therapy in hypertensives with left ventricular hypertrophy (LVH). Aim. We investigated the long-term effects of an AIIRA-based therapy on left ventricular (LV) structure and geometry in previously, unsatisfactorily treated essential hypertensive patients. Methods: Sixty-eight consecutive patients referred to our hypertension hospital outpatient clinic with: (i) LVH (LV mass index, LVMI ≥51 g/m2.7 in men and ≥47 g/m2.7 in women), (ii) uncontrolled clinic blood pressure BP≥140 and/or 90mmHg) and (iii) antihypertensive therapy not including angiotensin-converting enzyme (ACE) inhibitors or AIIRAs were selected for this study. Two-dimensionally guided M-mode echocardiograms were carried out at baseline and after 6, 12, 18 and 24 months of follow-up. In all patients, losartan (50-100 mg/day, mean dose 82 mg/day) was added as first step to the previous therapy. Additional drugs, tailored to the single patient, were added, if necessary, to achieve target BP values (v140/90 mmHg). Results. Overall, 59 patients completed the study with the primary efficacy measurements (LVMI) at all appropriate times. A significant reduction in both clinic systolic BP and diastolic BP was found across the entire period of study respect to baseline (-17/10, -22/12, -24/13 and -26/14 mmHg at 6, 12, 18 and 24 months, p",
keywords = "Angiotensin II receptor blockade, Concentric hypertrophy, Hypertension, Left ventricular regression",
author = "Cesare Cuspidi and Stefano Meani and Cristiana Valerio and Veronica Fusi and Carla Sala and Meilikemu Maisaidi and Alberto Zanchetti",
year = "2006",
month = "4",
doi = "10.1080/08037050600593052",
language = "English",
volume = "15",
pages = "107--115",
journal = "Blood Pressure",
issn = "0803-7051",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients

AU - Cuspidi, Cesare

AU - Meani, Stefano

AU - Valerio, Cristiana

AU - Fusi, Veronica

AU - Sala, Carla

AU - Maisaidi, Meilikemu

AU - Zanchetti, Alberto

PY - 2006/4

Y1 - 2006/4

N2 - Background. The 2003 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines recommend angiotensin II receptor antagonists (AIIRAs) as a first-line therapy in hypertensives with left ventricular hypertrophy (LVH). Aim. We investigated the long-term effects of an AIIRA-based therapy on left ventricular (LV) structure and geometry in previously, unsatisfactorily treated essential hypertensive patients. Methods: Sixty-eight consecutive patients referred to our hypertension hospital outpatient clinic with: (i) LVH (LV mass index, LVMI ≥51 g/m2.7 in men and ≥47 g/m2.7 in women), (ii) uncontrolled clinic blood pressure BP≥140 and/or 90mmHg) and (iii) antihypertensive therapy not including angiotensin-converting enzyme (ACE) inhibitors or AIIRAs were selected for this study. Two-dimensionally guided M-mode echocardiograms were carried out at baseline and after 6, 12, 18 and 24 months of follow-up. In all patients, losartan (50-100 mg/day, mean dose 82 mg/day) was added as first step to the previous therapy. Additional drugs, tailored to the single patient, were added, if necessary, to achieve target BP values (v140/90 mmHg). Results. Overall, 59 patients completed the study with the primary efficacy measurements (LVMI) at all appropriate times. A significant reduction in both clinic systolic BP and diastolic BP was found across the entire period of study respect to baseline (-17/10, -22/12, -24/13 and -26/14 mmHg at 6, 12, 18 and 24 months, p

AB - Background. The 2003 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines recommend angiotensin II receptor antagonists (AIIRAs) as a first-line therapy in hypertensives with left ventricular hypertrophy (LVH). Aim. We investigated the long-term effects of an AIIRA-based therapy on left ventricular (LV) structure and geometry in previously, unsatisfactorily treated essential hypertensive patients. Methods: Sixty-eight consecutive patients referred to our hypertension hospital outpatient clinic with: (i) LVH (LV mass index, LVMI ≥51 g/m2.7 in men and ≥47 g/m2.7 in women), (ii) uncontrolled clinic blood pressure BP≥140 and/or 90mmHg) and (iii) antihypertensive therapy not including angiotensin-converting enzyme (ACE) inhibitors or AIIRAs were selected for this study. Two-dimensionally guided M-mode echocardiograms were carried out at baseline and after 6, 12, 18 and 24 months of follow-up. In all patients, losartan (50-100 mg/day, mean dose 82 mg/day) was added as first step to the previous therapy. Additional drugs, tailored to the single patient, were added, if necessary, to achieve target BP values (v140/90 mmHg). Results. Overall, 59 patients completed the study with the primary efficacy measurements (LVMI) at all appropriate times. A significant reduction in both clinic systolic BP and diastolic BP was found across the entire period of study respect to baseline (-17/10, -22/12, -24/13 and -26/14 mmHg at 6, 12, 18 and 24 months, p

KW - Angiotensin II receptor blockade

KW - Concentric hypertrophy

KW - Hypertension

KW - Left ventricular regression

UR - http://www.scopus.com/inward/record.url?scp=33745107235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745107235&partnerID=8YFLogxK

U2 - 10.1080/08037050600593052

DO - 10.1080/08037050600593052

M3 - Article

VL - 15

SP - 107

EP - 115

JO - Blood Pressure

JF - Blood Pressure

SN - 0803-7051

IS - 2

ER -